Canada Has Around 2,000 Active Drug Shortages Right Now, Including Chemotherapy and Insulin

Canada has between 1,500 and 2,000 active drug shortages active right now in 2026, and five carry real clinical risk, according to the Canadian Pharmacists Association (CPhA). Four have reached Tier 3, Health Canada's highest severity classification. One has crossed a line pharmacists rarely encounter: a discontinuation with no replacement available. This article covers what is driving each shortage and what it means for the clinical teams managing patients through them.

What Counts as a Drug Shortage in Canada?

A drug shortage in Canada means a manufacturer cannot meet national demand for a product. Health Canada tiers shortages by clinical impact. Tier 3 is the highest level, reserved for shortages with the greatest risk to patients. Four of the five current shortages have reached Tier 3.

A Tier 3 label is not just paperwork. It triggers action between Health Canada, manufacturers, and pharmacy bodies. The alternative is patients going without medication that has no substitute. It also authorizes foreign imports of unapproved products and requires manufacturers to report on production timelines.

Why Cancer Patients Are Facing a Chemotherapy Drug Shortage

Cyclophosphamide has no single substitute that works across every protocol. It treats a range of cancers and autoimmune conditions. When the entire domestic supply chain fails at once, oncology pharmacists face a problem with no clean fix.

All three Canadian manufacturers, Baxter, Sterimax, and Andone Pharmaceuticals, are short across multiple vial sizes. Health Canada declared a Tier 3 shortage on February 20, 2026, and is working with manufacturers on mitigation strategies including importing foreign-authorized products. The shortage is expected to stay critical well into summer 2026.

When every domestic supplier is short at the same time, oncology pharmacists are left reallocating vial sizes and adjusting doses in real time. CPhA, the Canadian Society of Healthcare-Systems Pharmacy (CSHP), and the Canadian Association of Pharmacy in Oncology (CAPhO) have jointly developed clinical guidance to support that work. Health Canada is currently authorizing Andone to bring in UK-labelled cyclophosphamide (Seacross, 2000 mg) and Sandoz to import US-labelled cyclophosphamide as exceptional imports while monitoring domestic production timelines.

What's Behind the Ipratropium and Salbutamol Shortages

Two of Canada's most common respiratory therapies are in short supply at the same time. Both are under Tier 3 shortage. The cause is manufacturing disruptions, not a demand spike.

Ipratropium nebules are used daily by patients managing chronic obstructive pulmonary disease (COPD) and asthma. Teva and Pharmascience, the two major suppliers, are both reporting shortages tied to manufacturing disruptions, and Health Canada projects intermittent supply gaps to continue through 2026. Salbutamol, the fast-acting bronchodilator that relaxes airway muscles during a flare-up, has carried a Tier 3 designation since January 17, 2025 a shortage that remains unresolved more than 18 months on.

The two shortages together make the clinical risk worse. Nebule shortages pushed patients toward metered-dose inhalers, which compressed that supply too. Manufacturers are still managing tight inventories across both formats. When both a rescue inhaler and a daily nebulizer are short, teams substitute formats mid-treatment. That raises the risk of a patient arriving at an emergency room without their usual therapy on hand.

Why Opioid Combination Painkillers Are in Short Supply

Every major formulation of acetaminophen with oxycodone and acetaminophen with codeine is currently short nationwide. These are the combination painkillers commonly prescribed after surgery or injury, and the shortage reaches across the entire product category including Teva-Oxycocet, Apo-Oxycodone/Acet, Rivacocet, and the full Teva-Lenoltec line.

The shortage started with a manufacturing issue at one supplier, which pushed demand onto every other manufacturer. That surge created capacity constraints across the board. Supply is improving but constraints are expected to last for months.

For post-surgical pain, prescribers are switching to alternative formulations or non-opioid regimens earlier than they would otherwise. That transition requires clear communication between the prescribing team, pharmacy, and patient before discharge, not after the patient discovers their prescription cannot be filled.

Why Porcine Insulin Is Being Discontinued With No Replacement

The porcine insulin situation is not a shortage. It is a discontinuation. There is no replacement in Canada's standard formulary.

Wockhardt UK, the only global supplier of porcine insulin, told Health Canada in 2025 that it would no longer supply the Canadian market after switching its production from vials to insulin-pen cartridges. Health Canada extended availability by authorizing a temporary import of UK-labelled Hypurin Porcine Neutral, but that supply expired May 31, 2026 and has already run out.

For the small group of patients who cannot tolerate synthetic human or analog insulin, this is not a supply chain problem to work around. It is a slow-moving emergency. CPhA, CSHP, and the Canadian Society of Endocrinology and Metabolism have jointly published transition guidance for the patients affected. Health Canada is pursuing access through its Special Access Program, which lets patients with serious medical needs import unlicensed drugs. It says it is in talks with Wockhardt about supplying Hypurin through that route. Wockhardt had previously declined. No formal resupply agreement has been confirmed as of July 2026.

How Pharmacists Are Managing This at the Frontline

Every shortage above has a matching clinical resource. CPhA, working alongside CSHP, CAPhO, medSask, and Canada's endocrinology societies, has developed guidance documents for each of the five products, covering therapeutic alternatives, dosing adjustments, and patient counselling frameworks. That coordination work is what keeps a Tier 3 designation from becoming a treatment gap for most patients.

But guidance only helps if it reaches the right person at the right moment. During a dispensing decision or dosing adjustment, the team cannot stop to search a shared drive for the latest protocol version. When guidance lives in static PDFs sent by email, teams cross-reference manually while a patient waits.

Structured, searchable HIPAA-compliant communication tools that surface current shortage status and matching clinical guidance at the point of care reduce that lag. The difference between a shortage being managed and a shortage becoming a patient safety event often comes down to whether the right clinical information reached the right team member before the decision was made, not after the decision has been made.

What Health System Leaders Should Take From This

Five products across oncology, respiratory care, pain management, and endocrinology being constrained at the same time is not a coincidence of bad timing. It reflects how concentrated Canada's manufacturing base is for essential medications. When one supplier fails, there is often no backup domestic source.

Canada's small market size means fewer manufacturers compete for each product. The buffer when one fails is thin. The systemic issues facing Canadian healthcare extend well beyond staffing and funding, and supply chain fragility is now one of the most operationally urgent.

With 1,500 to 2,000 shortages active at any given time, the question for health leaders is not whether the next shortage arrives. It is whether frontline teams can act on it before it becomes a patient safety problem. Shortages become harmful when the information lag is longer than the decision window. Poor communication in healthcare already costs the system an estimated $1.7 billion annually drug shortage mismanagement adds to that toll in ways that are measurable and preventable.

The evidence on patient safety failures consistently points to the same root cause: the right information did not reach the right person in time. Drug shortages are a supply chain problem. How healthcare teams respond to them is a communication problem.